Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
Provided By GlobeNewswire
Last update: Aug 12, 2025
WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced second quarter 2025 financial results and recent developments.
Read more at globenewswire.com
